Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.2652W HIGH $29.65
Volume
2.90 M
Value Traded
52.44 M
Short % Float
18.15%
-5%Week
-17.97%1 Month
+1.72%3 Month
-18.27%6 Month
-82.34%5 Year
-92.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.09 B
EPS (TTM)
-0.91
P/E Ratio
-
Ent. Value
1.24 B
Total Shares
69.59 M
Float Shares
68.72 M
Insiders
1.24%
Institutions
114.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TNDM Catalyst Timeline
Dated clinical, regulatory and corporate events for Tandem Diabetes Care, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tandem Diabetes Care, Inc.
9Total events
0Upcoming
3Tier-1 (high impact)
2026 to 2026Coverage
Event history 8
●R&D DayPresentation
Management to present company update at Canaccord Genuity's 46th Annual Growth Conference
▲Product LaunchPost-Market
Launch of t:slim X2 insulin pump compatibility with Abbott FreeStyle Libre 3 Plus sensor in five international markets
diabetessource ↗
●NDA SubmissionRegulatory Filing
510(k) submitted to FDA for Tandem Mobi tubeless capability
diabetessource ↗
▲FDA ApprovalControl-IQApprovedFDA Decision
FDA clearance for Control-IQ+ use in type 1 diabetes during pregnancy
type 1 diabetes during pregnancysource ↗
▲EU ApprovalControl-IQApprovedEx-US Regulatory
CE Mark for Control-IQ+ use in type 1 diabetes during pregnancy
type 1 diabetes during pregnancysource ↗
▲Product LaunchPost-Market
Launched t:slim X2 compatibility with Abbott FreeStyle Libre 3 Plus Sensor in four European markets
diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How TNDM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Tandem Diabetes Care, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TNDM program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vosseller LeighOfficer (EVP & CHIEF FINANCIAL OFFICER) | Option | 1,496 50,895 held | $0.00 | 08/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TNDM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.3 % (50 %) | 8.68 M | 575.00 K | 187.5% ( 375.00 K) |
TNDM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TNDM ranks across every disease it competes in
Competitive Position is a premium feature
See how TNDM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTNDM News
TNDMTandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Tandem Diabetes Care, Inc. will announce its third quarter 2026 financial results on November 5, 2026, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results. This event highlights the company's ongoing commitment to transparency and stakeholder engagement.
Read more →TNDM▲ +19.1%on this news
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
Tandem Diabetes Care reported strong financial results for Q2 2026, with worldwide sales of $254.6 million, including $179.3 million from the U.S. The company achieved a gross margin of 57%, reflecting a significant increase from the previous year. Additionally, over 33,000 insulin pumps were shipped globally, showcasing the company's growth in the diabetes technology market.
Read more →TNDMTandem Diabetes Care Announces Upcoming Conference Presentation
Tandem Diabetes Care, Inc. has announced its participation in Canaccord Genuity's 46th Annual Growth Conference, scheduled for August 11, 2026. The management will provide a company update during the presentation, which will be available via live webcast and archived for 30 days. This engagement highlights the company's commitment to transparency and investor relations.
Read more →TNDMTandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care has announced the launch of the t:slim X2 insulin pump's compatibility with the Abbott FreeStyle Libre 3 Plus sensor. This development marks a significant step in diabetes management, as it will be available in five international markets. The integration aims to improve user experience and enhance diabetes care.
Read more →TNDMTandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
Tandem Diabetes Care has scheduled the announcement of its financial results for the second quarter of 2026 on August 6, 2026. This announcement is part of the company's regular reporting schedule. Further details regarding the financial performance will be provided at that time.
Read more →TNDMTandem Diabetes Care Announces First Quarter 2026 Financial Results
Tandem Diabetes Care has announced its financial results for the first quarter of 2026. The report includes key metrics and insights into the company's performance during this period. Specific details regarding revenue, expenses, and future outlook were not disclosed in the provided text.
Read more →TNDMTandem Diabetes Care Announces Upcoming Conference Presentations
Tandem Diabetes Care, Inc. has announced its participation in two upcoming investor conferences. The company will present updates at the BofA Securities 2026 Health Care Conference on May 12, 2026, and at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Both presentations will be available via live webcast and archived for 30 days.
Read more →TNDMTandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
Tandem Diabetes Care is set to announce its financial results for the first quarter of 2026 on May 7, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the results will be disclosed during the announcement.
Read more →TNDM▼ -9.9%on this news
Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Tandem Diabetes Care, Inc. regarding possible securities fraud, following a significant drop in the company's stock value. This decline was triggered by news of a malfunction in several insulin pumps that could lead to severe health risks such as hyperglycemia. Affected customers were notified before the public announcement, raising concerns about the company's transparency. Investors are encouraged to contact the law firm for potential claims related to this issue.
Read more →TNDMTandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032
Tandem Diabetes Care announced the pricing of $265 million in Convertible Senior Notes due 2032, up from an initial $200 million offering. The proceeds will be used for corporate purposes, including capped call transactions to offset potential dilution. The sale is expected to close on February 27, 2026, subject to customary conditions.
Read more →TNDM▲ +15%on this newsshared move
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
Tandem Diabetes Care, Inc. announced a proposed private placement of $200 million in convertible senior notes due 2032, subject to market conditions. The company will also grant initial purchasers an option for an additional $30 million in notes. Proceeds are expected to fund capped call transactions and support general corporate purposes. The notes will be unsecured obligations of Tandem with interest payable semiannually, and may convert into cash, shares, or a combination thereof.
Read more →TNDMTandem Diabetes Care Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance
Tandem Diabetes Care, Inc. reported strong financial results for Q4 2025 and provided 2026 guidance. Sales reached a record $290.4 million, bolstered by significant operational improvements and product innovations. Despite achieving a positive adjusted EBITDA and a record gross margin of 58%, the company faced a net loss and operating losses for the year. Looking ahead, Tandem aims to grow shipments and navigate a new pay-as-you-go pharmacy model in 2026.
Read more →TNDMTandem Diabetes Care Announces Appointment of Sandra Beaver to Board of Directors
Tandem Diabetes Care has appointed Sandra Beaver to its Board of Directors, effective November 7, 2025. Ms. Beaver, an independent director, will contribute her extensive experience in finance and healthcare, serving on both the Audit Committee and Cybersecurity and Data Oversight Committee. The leadership of Tandem highlighted her dynamic capabilities, expecting her to facilitate the company’s growth and market expansion. Beaver's background includes roles at Lyra Health and Evolus, making her a valuable addition to the team as they focus on innovative diabetes solutions.
Read more →TNDM▼ -9.1%on this news· ran to +19% by day 3
Tandem Diabetes Care Announces Third Quarter 2025 Financial Results
Tandem Diabetes Care, Inc. reported strong third quarter results with record sales and gross margin improvements for the period ending September 30, 2025. The company's achievements include expanded pharmacy benefit coverage and successful FDA clearances for several product offerings. Despite these positive outcomes, Tandem faces ongoing challenges, including a net loss of $21.2 million and adjustments to its financial guidance, impacted by IPR D expenses. Overall, Tandem's proactive strategic initiatives position it well for future growth in the diabetes technology market.
Read more →TNDM▼ -9.9%on this news
Tandem Diabetes Care Inc. (TNDM) - Product Pipeline Analysis Report 2025
Tandem Diabetes Care Inc. has been highlighted in the "Product Pipeline Analysis, 2025 Update" report, showcasing its commitment to revolutionizing diabetes management through advanced technology. The report details Tandem's innovative products like the Tandem Mobi system and t:slim X2 insulin pump, both utilizing Control-IQ technology. It also presents insights into the company’s pipeline products, clinical trials, and competitive landscape, aimed at aiding stakeholders in making informed decisions. The report underscores the company's extensive resources in education, marketing, and strategic planning.
Read more →TNDM▼ -5%on this news· ran to -33% by day 3shared move
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance
Tandem Diabetes Care, Inc. reported its second quarter 2025 financial results with record sales of $240.7 million, reflecting growth in both the U.S. and international markets. The company also provided guidance expecting total sales to reach $1 billion for the full year. Despite this growth, Tandem experienced increased operating and net losses compared to the previous year. The introduction of a new insulin pump with cutting-edge technology could further enhance its market position.
Read more →TNDMTandem Diabetes Care Announces First Quarter 2025 Financial Results
Tandem Diabetes Care, Inc. reported its financial results for the first quarter of 2025, showcasing a significant growth with worldwide sales reaching $234.4 million, a 22% increase year-over-year. The company's adjusted EBITDA margin improved, and 30% of U.S. lives are now covered through pharmacy benefits for Tandem Mobi. However, the operating loss expanded to $120.9 million and net loss also increased to $130.6 million compared to the previous year. Despite these losses, the company reaffirms its full-year guidance with anticipated sales between $997 million and $1.007 billion.
Read more →TNDMTandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance
Tandem Diabetes Care, Inc. reported strong financial performance for the fourth quarter and full year 2024, with record sales and significant growth in pump shipments. The company achieved a 44% increase in worldwide GAAP sales in Q4 2024 compared to the previous year, alongside successful new FDA clearances. Despite these positive results, Tandem faced operational losses and anticipates challenges related to their expansion into international markets. The company provided guidance for 2025, estimating sales between $997 million and $1.007 billion while acknowledging the impact of certain non-cash charges on financial performance.
Read more →TNDMTANDEM DIABETES CARE, INC. Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited) Table D ($'s in thousands) Three Months Ended September 30, Nine months ended
Tandem Diabetes Care, Inc. has announced its financial results for the third quarter of 2024, reporting a significant increase in GAAP sales by 31% to $244.0 million compared to the same period in 2023. The company also experienced a growth of over 25% in worldwide pump shipments and achieved a positive Adjusted EBITDA. Additionally, it has raised its full-year sales guidance for 2024 while reaffirming other financial forecasts. The company completed a clinical study to expand the Control-IQ indication for type 2 diabetes.
Read more →About Tandem Diabetes Care, Inc.
Headquarters12400 HIGH BLUFF DRIVE, San Diego, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next TNDM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime